nivolumab,ipilimumab
bms
['niche-2']
fully agree with on astonishing niche-2 results and future perspectives of neoadjuvant treatment 
MD, PhD. GI Medical Oncologist - Abdominal Medical Oncology Unit - INT Fondazione G. Pascale - Napoli @istitutotumori